goiter%20nontoxic%20(simple)--%20diffuse%20-and-%20multinodular
GOITER NONTOXIC (SIMPLE): DIFFUSE & MULTINODULAR
Nontoxic goiter is thyroid enlargement unrelated to hypothyroidism, hyperthyroidism, inflammation or neoplasia.
Etiology is usually unknown. Some known causes include iodine deficiency, iodine excess, goitrogen ingestion, autoimmune disorders, thyroid hormone production defects and certain medications.
It is usually asymptomatic.
Symptomatic patient may present with painless neck swelling, cosmetic complaints, shortness of breath, sudden increase in goiter size with pain due to hemorrhage, larger goiter causing obstructive signs eg dysphagia, choking sensation and Pemberton's sign.

Introduction

  • Thyroid enlargement unrelated to hypothyroidism, hyperthyroidism, inflammation or neoplasia

Etiology

  • Etiology is usually unknown
    • Known causes include: Iodine deficiency, iodine excess, goitrogen ingestion, autoimmune disorders, thyroid hormone production defects & certain medications

Signs and Symptoms

  • Usually asymptomatic
  • Symptomatic patient may present w/ the following:
    • Painless neck swelling
    • Cosmetic complaints
    • Shortness of breath
    • Sudden increase in goiter size w/ pain due to hemorrhage
    • Large goiter causing obstructive signs eg dysphagia, choking sensation, stridor, plethora (venous congestion)
    • Pemberton’s sign - faintness w/ facial congestion, external jugular venous blockage when both arms are raised above head (an action that draws the thyroid into the thoracic inlet)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.